Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme. To give you a teaser of what is to come, we are taking a closer look at the plenary speakers in the ALS-FTD sessions at the Symposium. In this blog, we explore the topics they will be presenting and find out a little more about the speakers.
Author: Eleanor Green
I work in the Research Development team at the MND Association as a Senior Research Co-ordinator. I completed my undergraduate degree in Biomedical Science and I became very interested in neuroscience throughout my degree. Following on from this, I did a Master’s degree in Molecular Medicine, with a focus on gene therapies. As part of my role, I identify interesting updates in MND research and communicate these via the blog in an understandable and engaging way.
34th Symposium: Basel Causes and disease mechanisms Markers of Disease Progression MND Research Symposium
Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 1
Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme.
Some people with ALS, the most common form of MND, also develop a form of dementia known as frontotemporal dementia (FTD). FTD is a group of disorders where the nerve cells in two sets of lobes (frontal and temporal) in the brain are damaged. In a similar way to how motor neurones break down in MND and cause loss of function in muscles, the damage to the nerve cells in FTD causes the connections between parts of the brain to break down. As more cells become damaged and die this can lead to symptoms such as problems with memory, thinking or language, changes in mood, emotions and behaviour.
34th Symposium: Basel Causes and disease mechanisms Clinical Trials Events Genetic Research Markers of Disease Progression MND Research Symposium
Symposium Preview: Meet the ALS/MND Plenary Speakers…Part 2
Reading Time: 7 minutes Each year we invite plenary speakers who are experts in their fields to provide an overview on topics across MND research and clinical practice. This year we have 14 plenary speakers talking about ALS/MND who will discuss a wide range of topics from genetics to tissue biomarkers to improving clinical practice. In this second blog we will be taking a closer look at some of our plenary speakers this year and sharing more about the topics they will be discussing.
34th Symposium: Basel Causes and disease mechanisms Events Genetic Research Healthcare Markers of Disease Progression MND Research Models of MND Symposium
Symposium Preview: Meet the ALS/MND Plenary Speakers…Part 1
Reading Time: 7 minutes As the research team count down to this year’s International Symposium on ALS/MND, we will be posting blogs throughout November to give you a snapshot
Reading Time: 6 minutes On the 8 September 2023, members of the Research Development team at the MND Association attended the 4th UCL Queen Square Motor Neuron Disease Centre
Causes and disease mechanisms Genetic Research Markers of Disease Progression MND Research Models of MND Research we fund Treatments Unproven treatments
A stepping stone to becoming future leaders in MND research
Reading Time: 6 minutes MND is a very complex disease and collaboration within the research community is key to building on our current understanding of the disease biology and
Reading Time: 6 minutes QurAlis, a biotechnology company focused on developing precision medicines for MND and other neurodegenerative diseases, has announced the opening of a clinical trial in the
Reading Time: 7 minutes Clinical trials are vital in the hunt for effective treatments of motor neurone disease. They provide the evidence needed to determine whether a drug is
Reading Time: 5 minutes The MND clinical trial landscape has grown vastly over the last decade and this has led to increased opportunities for people with MND to take
Reading Time: 6 minutes To fight motor neurone disease, we need a steady stream of enthusiastic and passionate scientists who can bring new ideas and push boundaries. Often, we